Q32 Change In Working Capital from 2010 to 2024
| QTTB Stock | 26.91 0.01 0.04% |
Change In Working Capital | First Reported 2010-12-31 | Previous Quarter -7.2 M | Current Value -6.8 M | Quarterly Volatility 11.5 M |
Check Q32 Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Q32 Bio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 549.1 K, Gross Profit of 549.1 K or Other Operating Expenses of 72.2 M, as well as many indicators such as Price To Sales Ratio of 28.89, Dividend Yield of 0.0 or PTB Ratio of 0.46. Q32 financial statements analysis is a perfect complement when working with Q32 Bio Valuation or Volatility modules.
Q32 | Change In Working Capital |
Latest Q32 Bio's Change In Working Capital Growth Pattern
Below is the plot of the Change In Working Capital of Q32 Bio over the last few years. It is the difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities. Q32 Bio's Change In Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Q32 Bio's overall financial position and show how it may be relating to other accounts over time.
| Change In Working Capital | 10 Years Trend |
|
Change In Working Capital |
| Timeline |
Q32 Change In Working Capital Regression Statistics
| Arithmetic Mean | 5,355,584 | |
| Geometric Mean | 2,820,973 | |
| Coefficient Of Variation | 215.46 | |
| Mean Deviation | 8,309,816 | |
| Median | 928,479 | |
| Standard Deviation | 11,538,886 | |
| Sample Variance | 133.1T | |
| Range | 41.9M | |
| R-Value | 0.11 | |
| Mean Square Error | 141.7T | |
| R-Squared | 0.01 | |
| Significance | 0.70 | |
| Slope | 279,667 | |
| Total Sum of Squares | 1864T |
Q32 Change In Working Capital History
About Q32 Bio Financial Statements
Q32 Bio stakeholders use historical fundamental indicators, such as Q32 Bio's Change In Working Capital, to determine how well the company is positioned to perform in the future. Although Q32 Bio investors may analyze each financial statement separately, they are all interrelated. For example, changes in Q32 Bio's assets and liabilities are reflected in the revenues and expenses on Q32 Bio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Q32 Bio. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Change In Working Capital | -7.2 M | -6.8 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Q32 Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Q32 Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Q32 Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Q32 Bio Stock:Check out the analysis of Q32 Bio Correlation against competitors. For information on how to trade Q32 Stock refer to our How to Trade Q32 Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Q32 Bio. If investors know Q32 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Q32 Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.50) | Revenue Per Share (1.24) |
The market value of Q32 Bio is measured differently than its book value, which is the value of Q32 that is recorded on the company's balance sheet. Investors also form their own opinion of Q32 Bio's value that differs from its market value or its book value, called intrinsic value, which is Q32 Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Q32 Bio's market value can be influenced by many factors that don't directly affect Q32 Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Q32 Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Q32 Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Q32 Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.